Hikma is a global pharmaceutical company that manufactures high-quality generic medicines and makes them accessible to people who need them.

London, 26 December 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has received FDA approval for and launched its generic version of Victoza®, Liraglutide Injection, in a 6 mg/mL dosage in the US. Liraglutide Injection, a Glucagon-Like Peptide-1 (GLP-1) product, is indicated as an adjunct to diet and exercise to improve glycemic control in adults and ...

Last reviewed: July 1, 2024. Policies that regulate Hikma colleagues' interactions with health care professionals in the United States reflect our commitment to compliance with applicable federal and state laws and regulations.

We successfully passed FDA inspections for our manufacturing plants in Saudi Arabia and Portugal. Our Injectables business also expanded into the lyophilised segment of the injectables market with the acquisition of a specialised manufacturing plant in Italy, and we moved into the oncology market with the acquisition of Ribosepharm GmbH and Thymoorgan in Germany.

Somos uma companhia global, com presença local em Portugal desde 1990. UAtravés da criação de medicamentos de alta qualidade e da disponibilização às pessoas que deles necessitam, ajudamos a moldar um mundo mais saudável que beneficia todas as nossas comunidades.

Last reviewed: July 1, 2024. Policies that regulate Hikma colleagues' interactions with health care professionals in the United States reflect our commitment to compliance with applicable federal and state laws and regulations.

Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA Press Release, Business Development 09 April 2025 Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA; Hikma launches Cisatracurium Besylate Injection, USP in the US Press Release, Product 25 March 2025 Hikma launches Cisatracurium Besylate ...

Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA Press Release, Business Development 09 April 2025 Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA; Hikma launches Cisatracurium Besylate Injection, USP in the US Press Release, Product 25 March 2025 Hikma launches Cisatracurium Besylate ...

In Deutschland arbeiten ca. 150 Mitarbeiter an 2 Standorten. Die Hikma Pharma GmbH befindet sich in München und ist seit 2005 auf dem deutschen Markt präsent. 2007 wurde die Ribosepharm von der Hikma Pharma GmbH übernommen und anschließend die Unternehmensbereiche zusammengelegt.

Legal Disclaimer - Hikma Employment Openings. There have been a number of recent incidents of fraud involving individuals and organizations offering false employment opportunities at Hikma.